Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia

Published:2024-06-03 Issue:7 Volume:23 Page:2495-2504
ISSN:1535-3893
Container-title:Journal of Proteome Research
language:en
Short-container-title:J. Proteome Res.

Author:

Narayanan Nisha¹²^ORCID,Marvin-Peek Jennifer³,Abouelnaaj Mohamad K.¹⁴,Majid Dhabya¹,Wang Bofei¹,Brown Brandon D.⁵^ORCID,Qiu Yihua¹,Kornblau Steven M.¹,Abbas Hussein A.¹⁶

Affiliation:

1. Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

2. The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

3. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

4. University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas 77030, United States

5. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

6. Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

Funder

University of Texas MD Anderson Cancer Center

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.4c00130

Reference44 articles.

1. Acute myeloid leukaemia in adults

2. Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML

3. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

4. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation

5. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML